Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07240857 | A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | enrolling by invitation | Early Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06434376 | MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis | enrolling by invitation | Early Phase 1 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07371247 | Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy | enrolling by invitation | Early Phase 1 | 65 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07356466 | Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma(FUGES032) | enrolling by invitation | Early Phase 1 | 100 | Fujian Medical UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT07285434 | Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer(Microlyvaq™) | enrolling by invitation | Early Phase 1 | 90 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07254104 | Clinical Evaluation of [68Ga]Ga-NOTA-RF PET Imaging Targeting RFVT3 in Patients With Pituitary Tumors | enrolling by invitation | Early Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07023848 | PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors | enrolling by invitation | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07023861 | The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies | enrolling by invitation | Early Phase 1 | 20 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07023068 | ⁶⁸Ga-DPA in the Lung Cancer Diagnosis | enrolling by invitation | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT06864572 | [68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer | enrolling by invitation | Early Phase 1 | 40 | Peking Union Medical College HospitalOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06747832 | INK Cells As Maintenance Therapy After Chemoradiotherapy for Small Cell Lung Cancer(iNK-SCLC) | enrolling by invitation | Early Phase 1 | 10 | Guangzhou Ruixin Biotechnological Co., LTDINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2026source: clinicaltrials